Prognosis
Vertex Seeks Trials of Therapies for Cystic Fibrosis, Diabetes
This article is for subscribers only.
Vertex Pharmaceuticals Inc. plans to seek permission from U.S. regulators next year to advance two experimental therapies for cystic fibrosis and Type 1 diabetes into human trials.
The Boston-based biotech is conducting studies to support investigational new drug applications, which drugmakers are required to submit before studying experimental therapies in humans, Vertex Chief Operating Officer Stuart Arbuckle said in an interview Tuesday.